Literature DB >> 24266710

Eosinophil activities modulate the immune/inflammatory character of allergic respiratory responses in mice.

E A Jacobsen1, W E Lesuer, L Willetts, K R Zellner, K Mazzolini, N Antonios, B Beck, C Protheroe, S I Ochkur, D Colbert, P Lacy, R Moqbel, J Appleton, N A Lee, J J Lee.   

Abstract

BACKGROUND: The importance and specific role(s) of eosinophils in modulating the immune/inflammatory phenotype of allergic pulmonary disease remain to be defined. Established animal models assessing the role(s) of eosinophils as contributors and/or causative agents of disease have relied on congenitally deficient mice where the developmental consequences of eosinophil depletion are unknown.
METHODS: We developed a novel conditional eosinophil-deficient strain of mice (iPHIL) through a gene knock-in strategy inserting the human diphtheria toxin (DT) receptor (DTR) into the endogenous eosinophil peroxidase genomic locus.
RESULTS: Expression of DTR rendered resistant mouse eosinophil progenitors sensitive to DT without affecting any other cell types. The presence of eosinophils was shown to be unnecessary during the sensitization phase of either ovalbumin (OVA) or house dust mite (HDM) acute asthma models. However, eosinophil ablation during airway challenge led to a predominantly neutrophilic phenotype (>15% neutrophils) accompanied by allergen-induced histopathologies and airway hyper-responsiveness in response to methacholine indistinguishable from eosinophilic wild-type mice. Moreover, the iPHIL neutrophilic airway phenotype was shown to be a steroid-resistant allergic respiratory variant that was reversible upon the restoration of peripheral eosinophils.
CONCLUSIONS: Eosinophil contributions to allergic immune/inflammatory responses appear to be limited to the airway challenge and not to the sensitization phase of allergen provocation models. The reversible steroid-resistant character of the iPHIL neutrophilic airway variant suggests underappreciated mechanisms by which eosinophils shape the character of allergic respiratory responses.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma; eosinophil deficient; neutrophil; steroid resistant

Mesh:

Substances:

Year:  2013        PMID: 24266710      PMCID: PMC3944108          DOI: 10.1111/all.12321

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  39 in total

1.  Eosinophils in health and disease: the LIAR hypothesis.

Authors:  J J Lee; E A Jacobsen; M P McGarry; R P Schleimer; N A Lee
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

Review 2.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 3.  Evidence for phenotype-driven treatment in asthmatic patients.

Authors:  Sherif Gonem; Dhananjay Desai; Salman Siddiqui; Christopher C E Brightling
Journal:  Curr Opin Allergy Clin Immunol       Date:  2011-08

4.  CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling.

Authors:  Joanne C Masterson; Eóin N McNamee; Paul Jedlicka; Sophie Fillon; Joseph Ruybal; Lindsay Hosford; Jesús Rivera-Nieves; James J Lee; Glenn T Furuta
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

5.  A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration.

Authors:  Thorsten Buch; Frank L Heppner; Christine Tertilt; Tobias J A J Heinen; Marcel Kremer; F Thomas Wunderlich; Steffen Jung; Ari Waisman
Journal:  Nat Methods       Date:  2005-06       Impact factor: 28.547

6.  Cys-leukotrienes promote fibrosis in a mouse model of eosinophil-mediated respiratory inflammation.

Authors:  Sergei I Ochkur; Cheryl A Protheroe; Wen Li; Dana C Colbert; Katie R Zellner; Hua-Hao Shen; Andrew D Luster; Charles G Irvin; James J Lee; Nancy A Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

7.  TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice.

Authors:  Laura McKinley; John F Alcorn; Alanna Peterson; Rachel B Dupont; Shernaaz Kapadia; Alison Logar; Adam Henry; Charles G Irvin; Jon D Piganelli; Anuradha Ray; Jay K Kolls
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 8.  Targeting eosinophils in allergy, inflammation and beyond.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

Review 9.  Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans.

Authors:  Lyudmila Lyakh; Giorgio Trinchieri; Lisa Provezza; Giuseppe Carra; Franca Gerosa
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

10.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more
  34 in total

Review 1.  Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?

Authors:  Taku Kambayashi; Terri M Laufer
Journal:  Nat Rev Immunol       Date:  2014-10-17       Impact factor: 53.106

2.  Eosinophils downregulate lung alloimmunity by decreasing TCR signal transduction.

Authors:  Oscar Okwudiri Onyema; Yizhan Guo; Bayan Mahgoub; Qing Wang; Amir Manafi; Zhongcheng Mei; Anirban Banerjee; Dongge Li; Mark H Stoler; Melissa T Zaidi; Adam G Schrum; Daniel Kreisel; Andrew E Gelman; Elizabeth A Jacobsen; Alexander Sasha Krupnick
Journal:  JCI Insight       Date:  2019-06-06

Review 3.  Professional and 'Amateur' Antigen-Presenting Cells In Type 2 Immunity.

Authors:  Martijn J Schuijs; Hamida Hammad; Bart N Lambrecht
Journal:  Trends Immunol       Date:  2018-11-27       Impact factor: 16.687

4.  Molecular Biology of Eosinophils: Introduction.

Authors:  Paige Lacy; Helene F Rosenberg; Garry M Walsh
Journal:  Methods Mol Biol       Date:  2021

5.  Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.

Authors:  Eva Knuplez; Rebecca Krier-Burris; Yun Cao; Gunther Marsche; Jeremy O'Sullivan; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-03-05       Impact factor: 4.962

6.  Eosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge.

Authors:  Katsuyuki Takeda; Yoshiki Shiraishi; Shigeru Ashino; Junyan Han; Yi Jia; Meiqin Wang; Nancy A Lee; James J Lee; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2014-10-11       Impact factor: 10.793

7.  rBet v 1 immunotherapy of sensitized mice with Streptococcus thermophilus as vehicle and adjuvant.

Authors:  Claudia Petrarca; Emanuela Clemente; Valentina Toto; Manuela Iezzi; Cosmo Rossi; Stefania Zanotta; Gianni Mistrello; Ivan Zanoni; Francesca Granucci; Stefania Arioli; Diego Mora; Simone Guglielmetti; Roberto Paganelli; Mario Di Gioacchino
Journal:  Hum Vaccin Immunother       Date:  2014-03-06       Impact factor: 3.452

8.  Frontline Science: Eosinophil-deficient MBP-1 and EPX double-knockout mice link pulmonary remodeling and airway dysfunction with type 2 inflammation.

Authors:  Sergei I Ochkur; Alfred D Doyle; Elizabeth A Jacobsen; William E LeSuer; Wen Li; Cheryl A Protheroe; Katie R Zellner; Dana Colbert; HuaHao H Shen; Charlie G Irvin; James J Lee; Nancy A Lee
Journal:  J Leukoc Biol       Date:  2017-05-17       Impact factor: 4.962

Review 9.  Eosinophil granule proteins: form and function.

Authors:  K Ravi Acharya; Steven J Ackerman
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

Review 10.  Re-defining the unique roles for eosinophils in allergic respiratory inflammation.

Authors:  E A Jacobsen; N A Lee; J J Lee
Journal:  Clin Exp Allergy       Date:  2014-09       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.